Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15675854 | 0.83 | MEN1 (0.37) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 | |
| SCHEMBL9617796 | 0.76 | ALDH1A1 (0.35) | CYP3A4ADORA3MEN1KMT2ARECQL | |
| Hydrochloric Acid SCHEMBL6000655 | 0.75 | MEN1 (0.34) | ADORA3MEN1KMT2APMP22RECQL | |
| SCHEMBL17784420 | 0.71 | CTSK (0.31) | ADRA2AADORA3LMNA | |
| SCHEMBL6577796 | 0.71 | LMNA (0.51) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 | |
| SCHEMBL8050217 | 0.70 | CETP (0.42) | OPRM1GAA | |
| SCHEMBL6664270 | 0.70 | HSD11B1 (0.38) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 | |
| SCHEMBL18428687 | 0.68 | CHRM2 (0.40) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 | |
| SCHEMBL8470404 | 0.67 | CHRM2 (0.69) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 | |
| Hydrochloric Acid SCHEMBL9474056 | 0.67 | MEN1 (0.70) | CHRM2CHRM1CYP2C19CYP2D6CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030205-A1 | METHODS FOR THE TREATMENT OF HYPERHIDROSIS | ZINGER MENNI MENASHE (IL) | 2020-01-30 | — | — | US | disclosed |
| US-20180369097-A1 | METHODS FOR THE TREATMENT OF HYPERHIDROSIS | ZINGER MENNI MENASHE (IL) | 2018-12-27 | — | — | US | disclosed |
| US-10010494-B2 | Methods for the treatment of hyperhidrosis | ZINGER MENNI MENASHE (IL) | 2018-07-03 | — | — | US | disclosed |
| EP-2585010-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | Mahashabde, Anu (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120289568-A1 | COMBINATIONS OF OXYBUTYNIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER | THERAVIDA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2012154779-A1 | COMBINATIONS OF OXYBUTYNIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER | THERAVIDA. INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289564-A1 | COMBINATIONS OF OXYBUTYNIN AND SALIVARY STIMULANTS FOR THE TREATMENT OF OVERACTIVE BLADDER | THERAVIDA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2485595-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT | Merck Sharp & Dohme Corp. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORPORATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120107385-A1 | METHOD OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | TEVA WOMEN'S HEALTH, INC. | 2012-05-03 | — | — | US | disclosed |
| US-20120053534-A1 | INTRAVAGINAL DEVICES COMPRISING ANTICHOLINERGIC AGENTS, AND METHODS OF MAKING THEREOF | TEVA WOMEN'S HEALTH, INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2011163356-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | MAHASHABDE ANU (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011043942-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT | MERCK SHARP & DOHME CORP. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110021542-A1 | Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder | PELVIPHARM (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2106792-A1 | Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder | Pelvipharm (FR) | 2009-10-07 | — | — | EP | disclosed |
| US-20080207737-A1 | Methods for the Treatment of Hyperhidrosis | ZINGER MENNI MENASHE | 2008-08-28 | — | — | US | disclosed |
| EP-1951186-A2 | METHODS FOR THE TREATMENT OF HYPERHIDROSIS | Zinger, Menni Menashe (IL) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007046102-A2 | METHODS FOR THE TREATMENT OF HYPERHIDROSIS | ZINGER MENNI MENASHE (IL) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107385-A1 | METHOD OF TREATING CONDITIONS ASSOCIATED WITH OVERACTIVE BLADDER | ACHE, MMP1, CHRM3 | CHRM2 5/4885CHRM1 19/4885CYP2C19 1211/4885 |
| US-20120202819-A1 | COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONISTS AND AN ANTIMUSCARINIC AGENT | ADRB2, ADRB3, ADRA2A | CHRM2 7/4885CHRM1 12/4885CYP2C19 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.